CD33 and acute myeloid leukemia: In the pediatric setting, GO consolidation (4.5 mg/mq to 9 mg/mq per dose) after reduced-intensity conditioning and alloSCT was safe in pediatric patients with CD33+ AML [74] in CR1/CR2, with OS probability at 1 and 5 years of 78.0% and 61.0%, respectively [75].